AR128158A2 - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- AR128158A2 AR128158A2 ARP220103645A ARP220103645A AR128158A2 AR 128158 A2 AR128158 A2 AR 128158A2 AR P220103645 A ARP220103645 A AR P220103645A AR P220103645 A ARP220103645 A AR P220103645A AR 128158 A2 AR128158 A2 AR 128158A2
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- heterocyclic compound
- salt
- medicament
- prophylaxis
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 101000829153 Homo sapiens Somatostatin receptor type 5 Proteins 0.000 abstract 1
- 102100023806 Somatostatin receptor type 5 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. De forma específica, se proporciona un compuesto representado por la fórmula (1) que aparece a continuación, en donde cada símbolo es como se lo define en la presente, o una sal de él, un medicamento que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013224093 | 2013-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128158A2 true AR128158A2 (es) | 2024-03-27 |
Family
ID=51932560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104043A AR098215A1 (es) | 2013-10-29 | 2014-10-28 | Compuesto heterocíclico |
| ARP220103645A AR128158A2 (es) | 2013-10-29 | 2022-12-29 | Compuesto heterocíclico |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104043A AR098215A1 (es) | 2013-10-29 | 2014-10-28 | Compuesto heterocíclico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9120777B2 (es) |
| EP (1) | EP3063139B1 (es) |
| JP (1) | JP6450755B2 (es) |
| AR (2) | AR098215A1 (es) |
| CY (1) | CY1121279T1 (es) |
| DK (1) | DK3063139T3 (es) |
| ES (1) | ES2710657T3 (es) |
| HR (1) | HRP20190133T1 (es) |
| HU (1) | HUE041792T2 (es) |
| LT (1) | LT3063139T (es) |
| PL (1) | PL3063139T3 (es) |
| PT (1) | PT3063139T (es) |
| RS (1) | RS58321B1 (es) |
| SI (1) | SI3063139T1 (es) |
| SM (1) | SMT201900101T1 (es) |
| TR (1) | TR201901986T4 (es) |
| TW (1) | TWI668214B (es) |
| UY (1) | UY35801A (es) |
| WO (1) | WO2015064083A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013122029A1 (ja) * | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| US9605000B2 (en) | 2013-03-14 | 2017-03-28 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists |
| JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| US20230049619A1 (en) * | 2019-12-19 | 2023-02-16 | Universite De Strasbourg | Sigma-1 receptor ligands and uses thereof |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116354961B (zh) * | 2021-12-27 | 2025-07-25 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其药物组合物及用途 |
| WO2024204277A1 (ja) | 2023-03-27 | 2024-10-03 | 株式会社スコヒアファーマ | 成長ホルモン分泌促進剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| CN1902171A (zh) | 2003-11-10 | 2007-01-24 | 舍林股份公司 | 用作ccr－5拮抗剂的苄醚胺化合物 |
| KR101117931B1 (ko) * | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| US7862825B2 (en) | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| US7799806B2 (en) | 2007-04-04 | 2010-09-21 | Hoffmann-La Roche Inc. | Substituted n-benzyl piperidines as somatostatin receptor modulators |
| US20080306116A1 (en) | 2007-06-08 | 2008-12-11 | Christ Andreas D | Aryloxazole, aryloxadiazole and benzimidazole derivatives |
| TW200918062A (en) | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| WO2010129729A1 (en) | 2009-05-07 | 2010-11-11 | Merck Sharp & Dohme Corp. | Substituted spirocyclic amines useful as antidiabetic compounds |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| US9000175B2 (en) | 2010-11-26 | 2015-04-07 | Lupin Limited | Bicyclic GPR119 modulators |
| US9605000B2 (en) | 2013-03-14 | 2017-03-28 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists |
-
2014
- 2014-10-28 PL PL14800152T patent/PL3063139T3/pl unknown
- 2014-10-28 ES ES14800152T patent/ES2710657T3/es active Active
- 2014-10-28 PT PT14800152T patent/PT3063139T/pt unknown
- 2014-10-28 DK DK14800152.2T patent/DK3063139T3/en active
- 2014-10-28 TR TR2019/01986T patent/TR201901986T4/tr unknown
- 2014-10-28 UY UY0001035801A patent/UY35801A/es not_active Application Discontinuation
- 2014-10-28 JP JP2016526960A patent/JP6450755B2/ja active Active
- 2014-10-28 RS RS20190190A patent/RS58321B1/sr unknown
- 2014-10-28 LT LTEP14800152.2T patent/LT3063139T/lt unknown
- 2014-10-28 SM SM20190101T patent/SMT201900101T1/it unknown
- 2014-10-28 HR HRP20190133TT patent/HRP20190133T1/hr unknown
- 2014-10-28 US US14/525,593 patent/US9120777B2/en active Active
- 2014-10-28 WO PCT/JP2014/005438 patent/WO2015064083A1/en not_active Ceased
- 2014-10-28 AR ARP140104043A patent/AR098215A1/es active IP Right Grant
- 2014-10-28 TW TW103137143A patent/TWI668214B/zh active
- 2014-10-28 EP EP14800152.2A patent/EP3063139B1/en active Active
- 2014-10-28 HU HUE14800152A patent/HUE041792T2/hu unknown
- 2014-10-28 SI SI201431055T patent/SI3063139T1/sl unknown
-
2019
- 2019-02-14 CY CY20191100202T patent/CY1121279T1/el unknown
-
2022
- 2022-12-29 AR ARP220103645A patent/AR128158A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3063139T (lt) | 2019-02-25 |
| CY1121279T1 (el) | 2020-05-29 |
| EP3063139A1 (en) | 2016-09-07 |
| WO2015064083A1 (en) | 2015-05-07 |
| PL3063139T3 (pl) | 2019-05-31 |
| UY35801A (es) | 2015-06-30 |
| US20150119412A1 (en) | 2015-04-30 |
| EP3063139B1 (en) | 2018-11-21 |
| JP2016535040A (ja) | 2016-11-10 |
| PT3063139T (pt) | 2019-02-22 |
| ES2710657T3 (es) | 2019-04-26 |
| TR201901986T4 (tr) | 2019-03-21 |
| HUE041792T2 (hu) | 2019-05-28 |
| TW201542539A (zh) | 2015-11-16 |
| TWI668214B (zh) | 2019-08-11 |
| DK3063139T3 (en) | 2019-03-11 |
| SI3063139T1 (sl) | 2019-03-29 |
| US9120777B2 (en) | 2015-09-01 |
| RS58321B1 (sr) | 2019-03-29 |
| SMT201900101T1 (it) | 2019-02-28 |
| AR098215A1 (es) | 2016-05-18 |
| JP6450755B2 (ja) | 2019-01-09 |
| HRP20190133T1 (hr) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000206A (es) | Compuesto heterocíclico fusionado | |
| UY35774A (es) | Compuesto heterocíclico | |
| UY35995A (es) | Compuesto heterocíclico | |
| UY35589A (es) | Compuesto peptídico | |
| UY35801A (es) | Compuesto heterocíclico | |
| MX2018012379A (es) | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). | |
| CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| CR20140537A (es) | Compuesto heterocíclico nitrogenado | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| CO2017003699A2 (es) | Compuesto heterocíclico | |
| CL2015003483A1 (es) | Composiciones que comprenden tintes fotocrómicos para el tratamiento de superficies. | |
| DOP2015000140A (es) | Compuesto heterocíclico | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| UY37502A (es) | Dinucleótido cíclico | |
| MX379401B (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| MX2015016628A (es) | Metodo para tratar infeccion intracelular. | |
| UY35650A (es) | Compuesto heterocíclico | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| UY35165A (es) | Método profiláctico o terapéutico para el síndrome de sjogren | |
| RU2013110799A (ru) | Средство для профилактики и лечения диабета | |
| RU2014115406A (ru) | Применение 8-(трифторметил)бензо[f][1,2,3,4,5]пентатиепин-6-амина в качестве антидепрессанта | |
| UY35095A (es) | Compuestos heterocíclicos que contienen nitrógeno | |
| UA98922U (ru) | 2-((4-амино-5(4-нитро фенил)-1,2,4-триазол-3-ил)тио)ацетонитрил, проявляющая диуретическую активность |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |